and CEO Boehringer Ingelheim USA Corporation. "We look forward to embarking on our next decade of transformation for the patients we serve with Brian at the helm." "I'm elated to be joining ...

The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

Princeton-based qordata has appointed Michael T. O’Connor as its new CEO. With a distinguished career at the intersection of ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Boehringer Ingelheim has acquired drug discovery and ... Nerio Therapeutics co-founder and CEO Sanford Madigan said: “We ...

Germany’s Boehringer Ingelheim has made a move to expand its ... as part of Boehringer Ingelheim,” said Simon Ittig, CEO of T3 Pharma. “Being integrated with our partners at Boehringer ...

“We’re thrilled to announce our partnership with Boehringer Ingelheim,” said Dr Kärt Tomberg, CEO and Co-Founder, ExpressionEdits. “Our platform harnesses the potential of introns to ...

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year. "The p ...

“We are excited to collaborate with the innovative teams at Boehringer Ingelheim,” said Jens Frauenfeld, CEO of Salipro Biotech. “By combining our Salipro ® platform technology with ...